Consistency matters more than specific timing, though avoiding administration immediately after meals optimizes absorption
Without adequate glutathione, toxic metabolites build up faster than your body can eliminate them
We start by assessing your current treatment plan and health status, adjusting dosages, and creating a personalized weight loss strategy
Safe, Evidence-Based Dosing and Side Effect Management Compounded semaglutide follows the same clinical safety profile as branded formulations, with dose escalation typically beginning at 0.25 mg weekly and increasing in 0.25 mg increments every 4 weeks until therapeutic benefit stabilizes
We now have top line phase 3 data for retatrutide a triple (GIP, GLP-1, glucagon) agonist: At 40 weeks (efficacy estimand): ~16.8% weight loss ~1.9% A1c reduction We are entering a new phase: Multi-hormonal therapies Integrated obesity and diabetes care Precision approaches to cardiometabolic disease One pathway is not enough for a complex disease like obesity, and it is exciting to see a growing pipeline of therapies with distinct mechanisms
